Ocugen Inc. (OCGN): What Top Wall Street Players are Saying

Mizuho Securities believes biotech firm Ocugen Inc. (NASDAQ: OCGN) is undervalued. Its business prospects extend beyond the development of a COVID-19 vaccine. According to Mizuho, Ocugen is now being evaluated exclusively on the commercial possibilities of its COVID-19 vaccine, which is already licensed for adult use in Mexico and is being reviewed by Canadian regulators. […]

Fosters Research
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.